German drugmaker Biotest turns behind on Greece: CFO

<p>FRANKFURT (Reuters) – German drugmaker <span>Biotest</span> pronounced it is exiting a <span>Greek market</span> in Jul after a business there unsuccessful to compensate their bills, according to a journal interview.</p>
<p> “We told a Greek health method in Apr that we would exit a marketplace within 3 months if no payments were made,” Biotest’s Chief Financial Officer <span>Michael Ramroth</span> told Boersen-Zeitung in an talk published on Saturday.</p>
<p> “And we don’t trust that manna will tumble from sky in June.”</p>
<p> Greece has unsuccessful to puncture a approach out of a low mercantile predicament and has left delinquent many bills sent to state-run hospitals for a smoothness of drugs and medical supplies.</p>
<p> Major drugmakers such as Bayer, <span>Merck KGaA</span> and Fresenius have pronounced they would continue ...